MAPT and Alzheimer disease: These biomarkers, associated with the biochemical diagnostic tools currently used for AD diagnosis (such as CSF biomarkers Aβ, tau, and p-tau), could be of particular interest for early diagnosis of AD or for patients presenting ambiguous profiles.